GLP Education
Semaglutide vs. tirzepatide: similar conversation, different mechanism.
Both medications are often grouped together in everyday conversation, but they do not act on exactly the same receptors.
Educational content • Last reviewed 2026-08-26
Semaglutide
Semaglutide acts as a GLP-1 receptor agonist. FDA-approved semaglutide products have specific labeled uses, which can include type 2 diabetes and chronic weight management depending on the product and patient.
Tirzepatide
Tirzepatide activates both GIP and GLP-1 receptors. FDA describes Zepbound’s mechanism through receptors for both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).
What that difference does—and does not—tell you
A different mechanism does not automatically mean one medication is right for a particular person. Medical history, goals, contraindications, side-effect profile, availability, approved indication, and clinician judgment all matter.
The compounded-drug distinction
Compounded drugs are not FDA-approved versions of branded medications. FDA has emphasized that compounded GLP-1 products do not undergo the same premarket review for safety, effectiveness, and quality as FDA-approved drugs. That makes clinician involvement and a properly licensed pharmacy especially important.
Common questions
Which one is better?
There is no universal answer. That is a clinical decision based on the person, the approved indication being considered, medical history, tolerability, and other factors.
Why do people call tirzepatide a GLP-2?
It is informal but incorrect shorthand. Tirzepatide is a dual GIP/GLP-1 receptor agonist.
Sources & further reading
Keep learning
Freedom Wellness
Not sure where to start?
You don’t need to figure out the wellness space alone. Tell us what you’re trying to accomplish and we’ll help you understand the available paths.